Despite many advances in the field of allogeneic hematopoietic stem cell transplantation (alloHSCT) only limited progress has been made in the treatment of steroid-refractory GvHD. Around 40-80% of transplant recipients experience grade II-IV acute GvHD (aGvHD), and a sustained response to first line corticosteroid treatment is achieved only in half of them. 1, 2 Grade IV steroidrefractory aGvHD is associated with particularly poor prognosis with a long-term survival of less than 10%. 3 We report the outcome of 30 consecutive adult and pediatric patients who were treated for steroid-refractory GvHD with third party bone marrow-derived, platelet-lysate (PL)-expanded mesenchymal stem cells (MSCs) in a prospective single-arm study. Adult patients had undergone allogeneic SCT for a malignant or non-malignant disease at Turku University Hospital or Helsinki University Hospital and pediatric patients at Helsinki Children's Hospital.
aGvHD was graded according to the Glucksberg criteria 4 and indications for MSC treatment were steroid resistance defined as progression or lack of response after five days of treatment with methylprednisolone 2 mg/kg, or recurrent aGvHD, while tapering steroid. Chronic GvHD (cGvHD) was graded according to the consensus criteria by the National Institute of Health. 5 Indications for MSC treatment in cGvHD were steroid resistance defined as a lack of response after 30 days on treatment, or steroid dependency defined as a progression when steroid was tapered. All patients or their legal guardians provided written informed consent for MSC treatment.
Allogeneic bone-marrow derived MSCs (LY-MSCs) were produced in the GMP facility of the Advanced Cell Therapy Centre, Finnish Red Cross Blood Service (FRCBS), Helsinki, Finland. The process development and main features of the clinical-grade LY-MSC production method based on platelet lysate has been described previously 6 and detailed protocol is presented in Supplementary Information. The aim was to provide a total of 6 doses of MSCs to each patient, administered according to a bi-weekly (aGvHD and cGvHD) or once-weekly (cGvHD) schedule. The target dose for each infusion was 2 × 10 6 cells/kg recipient body weight.
In aGvHD, responses to MSC therapy were evaluated on day 28 after the first MSC dose. 7 At this time point, organ specific stage and overall grade were recorded, and the responses were categorized as complete response (CR, complete resolution of symptoms), very good partial response (VGPR, decrease in overall grade ⩾ 2 grades), partial response (PR, improvement less than VGPR) and no response (NR). Patients were considered responders if they demonstrated at least PR. In cGvHD, organ specific and global severity scores were assessed at three months post treatment, and responses were classified as CR (resolution of all symptoms relating to cGvHD), PR (decrease in overall severity score or decrease of ⩾ 2 points in the sum of organ specific scores) and NR. Most patients received mold-active antifungal prophylaxis in addition to viral and pneumocystis pneumonia prophylaxis.
Statistical analyses were performed using the SPSS software package (IBM SPSS Statistics 21). Survival was calculated from the onset of GvHD to death. Survival curves were estimated with the Kaplan-Meier method and the log-rank test was applied to compare the survival of different groups. Surviving patients were censored at the time of last follow-up.
Twenty-two adults and eight children received MSCs as salvage therapy for steroid-refractory GvHD between January 2013 and August 2015. Twenty-six patients received treatment for aGvHD, four of which were classified as late-onset aGvHD. One pediatric patient had previously received two doses of decidual stromal cells 8 two months before MSC treatment. MSC therapy was given on the top of GvHD prophylaxis (Table 1) plus tapered corticosteroid dose. Four adult patients received treatment for cGvHD. A total of 133 infusions were administered. The median number of infusions per patient was 5 (range 1-6) and the median cell dose was 2.0 × 10 6 cells/kg (range 1.4-2.7 × 10 6 /kg). No immediate infusion-related or late toxicity was observed. Patient characteristics, grading of aGvHD and organ involvement is given in Table 1 . Majority of the patients (92%) suffered from grade III-IV aGvHD, and most of them had multiple involved organs with gastrointestinal affision in all. All but one adult (94% of the adult patients) presented with stage III-IV gut aGvHD. The median time from transplantation to the onset of aGvHD was 45 days (range 10-229 days), and 13 days (range 5-413 days) from the onset of aGvHD to MSC treatment. The patient with an exceptionally long time period from the onset of aGvHD to MSC treatment had a relapsing late onset aGvHD of the gut.
Overall, 62% of the aGvHD patients (16/26) showed a response at day 28 after MSC therapy: 27% CR, 15% VGPR and 19% PR (Table 1) . Conversely, 38% of the patients did not respond or progressed. The overall response rate was not statistically significantly different between adult and pediatric patients, 50 and 88%, respectively (P = 0.099, Table 1 ). The number of involved organs or overall aGvHD grade was not different between responding and non-responding patients (P = 0.774 and P = 0.990, respectively). Time from the onset of aGvHD to MSC treatment or number of infusions was not associated with the response (P = 0.320 and P = 0.376, respectively).
After the median follow-up of 767 days (range 74-1270 days) from aGvHD diagnosis, 42% (11/26) of the patients were alive. A significantly greater proportion of the pediatric patients survived compared to the adults, 88% and 22%, respectively (P = 0.003). The day 28 response among the 11 survivors was CR in 4, VGPR in 3, PR and NR in 2 patients, respectively. The estimated median survival after the onset of aGvHD was 424 days (95% CI 0-869 days; Figure 1a ) and 386 days after the last MSC dose (95% CI 0-808 days). Overall survival was significantly better in responders (median not reached) compared to non-responders (median of 82 days; 95% CI 36-128 days, P = 0.010; Figure 1b ). Children had significantly better survival than adults, median not reached versus a median of 92 days (95% CI 75-109 days, P = 0.004; Figure 1c ). In the whole aGvHD cohort the actual 6-month, 12-month and 24-month survivals after the onset of aGvHD were 54% (14/26), 48% (11/23), and 29% (6/21), respectively. Among adult patients the corresponding rates were 39% (7/18), 29% (5/17), and 18% (3/17), respectively. One child with Fanconi's anemia died of complications related to the primary disease during the follow-up. Among adult patients non-relapse mortality (NRM) was high irrespective of response to MSC treatment, being 56% in responders and 78% in non-responders (P = 0.620). However, causes of death differed significantly between responders and non-responders (P = 0.024). GvHD was the main cause of death among non-responders, and infection among responders. Infections among responding patients were caused by aspergillus, mucormycosis and resistant pseudomonas species (one each). These infections emerged 30-90 days after begin of MSC therapy; the methylprednisolone doses varied then from 0 to 32 mg/day. One additional death due to intracerebral hemorrhage occurred during a severe adenovirus infection. There was one death due to relapse/refractory disease among responders and nonresponders, respectively.
Four adult patients received MSCs for cGvHD, and all of them suffered from a severe disease. The median age was 44 years (range 37-63 years). Patients were heavily pretreated as all had received corticosteroids, mycophenolate mofetil and everolimus. One patient had also been treated with PUVA and photopheresis; one patient with tacrolimus, alemtuzumab and photopheresis; and one patient with monoclonal IL-6 antibody tocilizumab. The median time from the onset of cGvHD to MSC therapy was 222 days (44-287). Three patients died before response assessment at 3 months. The only evaluable patient did not fulfil the criteria for response, although minor improvement in his sclerotic skin lesions was observed. He later succumbed to cGvHD. The median survival after the diagnosis of cGvHD was 296 days (47-544 days). The cause of death was infection in two cases, and cGvHD and relapse in one patient each.
In conclusion, our study describes a good response rate of 62% at day 28 to MSCs in the treatment of steroid-refractory aGvHD, which is in agreement with the previously published data. [9] [10] [11] [12] [13] Higher response rates were seen in children than in adults with ORR of 88 versus 50% and CR of 38 versus 22%, respectively. However, in adults the benefit obtained with MSCs was partly offset by high infectious mortality. Patients with corticosteroidresistant GvHD are heavily immunocompromised and susceptible to infections, and MSCs may cause some additional impact on this status. After the median follow-up of 2 years, 22% (4/18) of the adults were alive in spite of fairly good response rates. Poor long term survival even in responding patients may imply that MSC treatment does not induce immune tolerance in severe aGvHD but rather temporarily breaks the vicious circle of GVH reaction. The efficacy of MSCs might be improved with a prolonged immunosuppressive therapy and highly effective infection prophylaxis. With our patient numbers we could not perform analyses to identify predictive factors for survival. Ultimately, randomised studies are needed to establish the role of MSCs in the treatment of steroid-resistant GvHD, against which no standard treatment can be recommended.
